News

ARCHIVE

October 3, 2024
The Benefits And Risks Of An LLC Business Model In Biotech
Life Science Leader
July 17, 2024
Biotech Breakthroughs: Jeb Keiper, CEO of Nimbus Therapeutics, Discusses Their Innovative Journey
Biotech 2050
June 3, 2024
After two Big Pharma deals, Nimbus looks to keep the hits coming
PharmaVoice
May 23, 2024
After $4B Takeda deal, Nimbus lays out ‘grand’ hopes for its next-gen immunotherapy drug
Endpoints News
February 28, 2024
Biotech’s top money raisers of 2023
Fierce Biotech
September 6, 2023
Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year
STAT
June 15, 2023
AI Drug Discovery Is a $50 Billion Opportunity for Big Pharma
Bloomberg Business
March 18, 2023
Takeda’s $4 Billion Psoriasis Pill Helped Clear Skin in Mid-Stage Study
Bloomberg Business
December 16, 2022
Nimbus CEO Jeb Keiper on negotiating a $4B deal and building an unorthodox biotech startup
BioPharma Dive
December 13, 2022
In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront
Endpoints
October 11, 2022
Sunny days for Nimbus: Lilly inks $496M biobucks deal for potential metabolic disease therapies
Biotech Insider
September 12, 2022
Nimbus Therapeutics raises $125m to test drug in psoriasis, lupus, and other diseases
The Boston Globe
September 12, 2022
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
BioPharma Dive
September 12, 2022
Nimbus clinches $125M raise via big donor-backed private financing round following Bristol Myers’ TYK2 approval
Endpoints
August 16, 2022
Nimbus Therapeutics Automates CRO Data Ingestion to Accelerate Deployment to Scientists
Egnyte
June 8, 2020
BIO: Nimbus CEO: ‘We’re not just a one-hit wonder’
FierceBiotech
June 8, 2020
Nimbus picks 4 preclinical targets for the next chapter of its pioneering computational drug discovery work
Endpoints
July 25, 2019
Celgene turns to Nimbus on ‘highly prized’ I/O target — landing right in Bristol-Myers’ sweet spot
Endpoints News
June 10, 2019
Discovery of Allosteric Inhibition of Human ATP-Citrate Lyase
Cell Press: Trends in Pharmacological Sciences
April 4, 2019
Nimbus exposes complete ACLY structure, discovers allosteric inhibitory sites
BioCentury
March 20, 2019
Nimbus builds out scientific team with new heads of biology, preclinical development
FierceBiotech
February 14, 2019
Nimbus brings on Janssen discovery head as CSO with plans to expand its portfolio
FierceBiotech
December 28, 2017
Can Innate Immune System Targets Turn Up the Heat on Cold Tumours?
Nature Reviews Drug Discovery
October 5, 2017
Nimble Move
BioCentury Innovations
October 3, 2017
Celgene joins the heavyweight partner club collaborating with Nimbus
Endpoints News
September 30, 2017
Don Nicholson of Nimbus: Making It Rain
Human Proof of Concept
September 26, 2017
The drug-maker’s guide to the galaxy
Nature
June 2, 2017
Gormley’s Take: Punching Back at Liver Cancer
WSJ Pro Venture Capital
April 5, 2017
Nimbus in full-on drug development partnership with Charles River
FierceBiotech
April 4, 2017
New England Venture Capital Association announces 2017 NEVY Awards nominees
Boston Business Journal
March 7, 2017
Gender tokenism and bias prevail in biotech boardrooms
Nature Biotech
February 17, 2017
Editorial: Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?
British Journal of Haematology
November 10, 2016
Cutting the cancer fat: A Nimbus-designed compound starves tumors of fatty acids
BioCentury Innovations
November 2, 2016
Nimbus Wins $200M Milestone Payment from Gilead toward ACC Inhibitor Program in NASH
Genetic Engineering & Biotechnology News
November 2, 2016
Gilead pays Nimbus $200M after fast progress in NASH
FierceBiotech
November 1, 2016
Gilead pays $200M milestone to Cambridge biotech Nimbus
Boston Business Journal
September 23, 2016
Stopping fat synthesis shrinks cancers, study finds
The San Diego Union-Tribune
May 13, 2016
Big Pharma Innovation in Small Places
Fortune
April 4, 2016
Gilead to buy Nimbus unit for up to $1.2b
The Boston Globe
April 4, 2016
Gilead paying up to $1.2B for Nimbus unit, drug candidate
Associated Press